NurExone Biologic (FRA:J90) Short Percentage of Float


FRA:J90 NurExone Biologic Inc FRA:J90
34 GF Score
Price €0.33
! 2 Warning Signs
View Full Analysis

What is NurExone Biologic Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:J90 vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, NurExone Biologic's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NurExone Biologic Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NurExone Biologic's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where NurExone Biologic's Short Percentage of Float falls into.


FRA:J90
34GF Score
NurExone Biologic Inc FRA:J90
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NurExone Biologic Business Description

Other Exchanges NRXBF:USANRX:Canada
Address 1 Adelaide Street East, Suite 801, Toronto, ON, CAN, M5C 2V9
NurExone Biologic Inc is a company that focuses on developing biological and minimally invasive treatments for Spinal Cord Injury and Traumatic Brain Injury. Its primary product is ExoTherapy, which is an exosome therapy production platform. It is developing ExoPTEN, a product that utilizes ExoTherapy for the treatment of acute Spinal Cord Injuries (SCI). It also aims to monetize its proprietary ExoTherapy technology and production platform by licensing it to the biopharmaceutical industry for other diseases and indications.
34GF Score

Get the complete analysis for FRA:J90

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.33
Price